Literature DB >> 8671650

HLA-DM and MHC class II molecules co-distribute with peptidase-containing lysosomal subcompartments.

M Fernandez-Borja1, D Verwoerd, F Sanderson, H Aerts, J Trowsdale, A Tulp, J Neefjes.   

Abstract

MHC class II molecules associate with peptides in the endocytic pathway. Different endosomal locations for peptide loading of class II molecules, varying from early endosomes (EE) to lysosomes, have been assigned on the basis of subcellular fractionation experiments. We have determined the intracellular location of HLA-DM, a molecule that supports peptide loading of class II molecules, by separating vesicles from the melanoma cell line Mel JuSo on the basis of buoying density and surface charge. In both fractionations, HLA-DM co-fractionated with a lysosomal compartment containing beta-hexosaminidase (beta-hex) activity and not with endosomes. Further analysis showed that HLA-DM mainly co-fractionated with a sub-lysosomal structure characterized by a relative low density and containing both pro- and mature cathepsin D and MHC class II molecules. Fluid phase markers first enter this compartment before entering high-density lysosomes that contain exclusively mature cathepsin D, some HLA-DM and no detectable MC class II molecules. Finally we determined the intracellular location of neutral and acidic peptidases. Whereas neutral peptidase activity was detected in the endoplasmic reticulum and/or plasma membrane fractions, acidic peptidase activity exclusively migrated at the position of HLA-DM containing lysosomal vesicles. Our results show that class II molecules co-migrate with HLA-DM, pro- and mature cathepsin D, beta-hex and acidic peptidase activity. HLA-DM, cathepsin d and class II molecules were not observed at the position of EE. Our data suggest that HLA-DM-mediated peptide loading of class II molecules occurs in a lysosomal subcompartment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671650     DOI: 10.1093/intimm/8.5.625

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  11 in total

1.  Kinetics and intracellular pathways required for major histocompatibility complex II-peptide loading and surface expression of a fluorescent hapten-protein conjugate in murine macrophage.

Authors:  D J Weaver; E W Voss
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

2.  Major histocompatibility class II molecules prevent destructive processing of exogenous peptides at the cell surface of macrophages for presentation to CD4 T cells.

Authors:  Alexei von Delwig; Julie A Musson; Joe Gray; Norman McKie; John H Robinson
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

3.  Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation.

Authors:  J Deussing; W Roth; P Saftig; C Peters; H L Ploegh; J A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

4.  Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions.

Authors:  Liusong Yin; Zachary J Maben; Aniuska Becerra; Lawrence J Stern
Journal:  J Immunol       Date:  2015-06-10       Impact factor: 5.422

5.  Identification of mycobacterial surface proteins released into subcellular compartments of infected macrophages.

Authors:  W L Beatty; D G Russell
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

6.  Direct vesicular transport of MHC class II molecules from lysosomal structures to the cell surface.

Authors:  R Wubbolts; M Fernandez-Borja; L Oomen; D Verwoerd; H Janssen; J Calafat; A Tulp; S Dusseljee; J Neefjes
Journal:  J Cell Biol       Date:  1996-11       Impact factor: 10.539

7.  Lysosomal rerouting of Hsp70 trafficking as a potential immune activating tool for targeting melanoma.

Authors:  Kata Juhász; Roland Thuenauer; Andrea Spachinger; Ernő Duda; Ibolya Horváth; Laszlo Vígh; Alois Sonnleitner; Zsolt Balogi
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 8.  Partnering for the major histocompatibility complex class II and antigenic determinant requires flexibility and chaperons.

Authors:  Scheherazade Sadegh-Nasseri
Journal:  Curr Opin Immunol       Date:  2021-06-17       Impact factor: 7.268

9.  Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism.

Authors:  J A Villadangos; R J Riese; C Peters; H A Chapman; H L Ploegh
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

10.  Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.

Authors:  M van Ham; M van Lith; B Lillemeier; E Tjin; U Grüneberg; D Rahman; L Pastoors; K van Meijgaarden; C Roucard; J Trowsdale; T Ottenhoff; D Pappin; J Neefjes
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.